



(51) International Patent Classification:

A61K 31/4412 (2006.01) C07D 403/02 (2006.01)

A61K 38/05 (2006.01) C07D 403/06 (2006.01)

A61P 43/00 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2019/045827

(22) International Filing Date:

09 August 2019 (09.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/717,697 10 August 2018 (10.08.2018) US

62/845,229 08 May 2019 (08.05.2019) US

(71) Applicant: SITARI PHARMA, INC. [US/US]; 11099 N.

Torrey Pines Road, Suite 290, La Jolla, CA 92037 (US).

(72) Inventors: CAMPBELL, David; 11099 N. Torrey Pines

Road, Suite 290, La Jolla, CA 92037 (US). CHAPMAN,

Justin; 11099 N. Torrey Pines Road, Suite 290, La Jolla,

CA 92037 (US). CHEUNG, Mui, H.; 1250 South Col-

legeville Road, Collegeville, PA 19426 (US). DIRAIMON-

DO, Thoams, R.; 11099 N. Torrey Pines Road, Suite 290,

La Jolla, CA 92037 (US). DURON, Sergio, G.; 1250 South

Collegeville Road, Collegeville, PA 19426 (US).

(74) Agent: DJUNG, Jane, F.; Glaxosmithkline, Global

Patents, UP4110, 1250 South Collegeville Road, Col-

legeville, PA 19426 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,

KM, ML, MR, NE, SN, TD, TG).

(54) Title: TRANSGLUTAMINASE 2 (TG2) INHIBITORS

(57) Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.